Literature DB >> 11735169

Pre-operative serum levels of sialyl Tn antigen predict liver metastasis and poor prognosis in patients with gastric cancer.

T Nakagoe1, T Sawai, T Tsuji, M Jibiki, A Nanashima, H Yamaguchi, T Yasutake, H Ayabe, K Arisawa, H Ishikawa.   

Abstract

AIMS: To clarify the prognostic value of preoperative serum levels of sialyl Tn antigen (STN) for survival of gastric cancer patients.
METHODS: Pre-operative serum levels of STN, sialyl Lewis(a)antigen (CA19-9) and carcinoembryonic antigen (CEA) were examined in 180 patients who underwent resection of gastric cancer. Patients were divided into high and low antigen groups on the basis of a selected diagnostic-based cut-off value. Correlation between high antigen serum levels, established clinicopathologic factors and prognosis was examined by univariate and multivariate analysis.
RESULTS: Twenty-eight patients (15.6%) were classified as high STN; 37 (20.6%) as high CA19-9; and 33 (18.3%) as high CEA. The survival time of the high STN, CA19-9 or CEA group was shorter than that of the respective low-antigen group (P<0.0001, P=0.0008 or P=0.0002, respectively). Patients with stage III/IV tumours with high STN had a shorter survival time that those with low STN (P=0.0004). Cox's regression with multiple covariates showed that high serum STN is an independent factor predicting a worse outcome in gastric cancer patients. Multiple logistic regression analysis revealed that high serum STN is an independent predictor for the development of liver metastasis.
CONCLUSIONS: Pre-operative high serum levels of STN predict both liver metastasis and poor prognosis after resection for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11735169     DOI: 10.1053/ejso.2001.1199

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  10 in total

Review 1.  Strategies for treating liver metastasis from gastric cancer.

Authors:  Yoshihiro Kakeji; Masaru Morita; Yoshihiko Maehara
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

2.  Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy.

Authors:  Seok Reyol Choi; Jin Seok Jang; Jong Hun Lee; Myung Hwan Roh; Min Chan Kim; Won Sup Lee; Waqar Qureshi
Journal:  Dig Dis Sci       Date:  2006-09-29       Impact factor: 3.199

3.  Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery.

Authors:  Diana Campos; Daniela Freitas; Joana Gomes; Ana Magalhães; Catharina Steentoft; Catarina Gomes; Malene B Vester-Christensen; José Alexandre Ferreira; Luis P Afonso; Lúcio L Santos; João Pinto de Sousa; Ulla Mandel; Henrik Clausen; Sergey Y Vakhrushev; Celso A Reis
Journal:  Mol Cell Proteomics       Date:  2015-03-26       Impact factor: 5.911

4.  alpha2,3 sialic acid processing enzymes expression in gastric cancer tissues reveals that ST3Gal3 but not Neu3 are associated with Lauren's classification, angiolymphatic invasion and histological grade.

Authors:  Michael W L Quirino; Amanda P B Albuquerque; Maria F D De Souza; Antônio F Da Silva Filho; Mário R Martins; Maira G Da Rocha Pitta; Michelly C Pereira; Moacyr J B De Melo Rêgo
Journal:  Eur J Histochem       Date:  2022-09-29       Impact factor: 1.966

5.  Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling.

Authors:  Christabelle Rajesh; Satish Sagar; Ashok Kumar Rathinavel; Divya Thomas Chemparathy; Xianlu Laura Peng; Jen Jen Yeh; Michael A Hollingsworth; Prakash Radhakrishnan
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 6.  Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association.

Authors:  Hideaki Shimada; Tamaki Noie; Manabu Ohashi; Koji Oba; Yutaka Takahashi
Journal:  Gastric Cancer       Date:  2013-04-10       Impact factor: 7.370

7.  CDw75 is a significant histopathological marker for gastric carcinoma.

Authors:  Lei Shen; Hai-Xia Li; He-Sheng Luo; Zhi-Xiang Shen; Shi-Yun Tan; Jie Guo; Jun Sun
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

Review 8.  Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy.

Authors:  Satoru Iwasa; Toshihiro Kudo; Daisuke Takahari; Hiroki Hara; Ken Kato; Taroh Satoh
Journal:  Int J Clin Oncol       Date:  2020-04-29       Impact factor: 3.402

9.  Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial.

Authors:  Nuhad K Ibrahim; James L Murray; Dapeng Zhou; Elizabeth A Mittendorf; Dory Sample; Michael Tautchin; David Miles
Journal:  J Cancer       Date:  2013-08-22       Impact factor: 4.207

10.  Sialyl-tn in cancer: (how) did we miss the target?

Authors:  Sylvain Julien; Paula A Videira; Philippe Delannoy
Journal:  Biomolecules       Date:  2012-10-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.